Orexo AB (CHIX:ORXS) Institutional Ownership: 2.76% (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:ORXS Orexo AB CHIX:ORXS
41 GF Score
Price kr30.95
GF Value kr7.46
! 7 Warning Signs
View Full Analysis

What is Orexo AB Institutional Ownership?

Orexo AB CHIX:ORXS 41 Institutional Ownership is 2.76% as of Jul. 22, 2026. GuruFocus rates CHIX:ORXS with a GF Score™ of 41/100 and a GF Value™ of kr7.46. The stock has 7 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Orexo AB's institutional ownership is 2.76%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Orexo AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Orexo AB's Float Percentage Of Total Shares Outstanding is 0.00%.

Orexo AB Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Orexo AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orexo AB Institutional Ownership Chart

Orexo AB Historical Data

The historical data trend for Orexo AB can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 2.42 2.76 2.76 2.80 2.93 2.95 2.79 2.76 2.76 2.76
CHIX:ORXS
41GF Score
Orexo AB CHIX:ORXS
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orexo AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 2.76% mean?
Orexo AB (CHIX:ORXS) has a Institutional Ownership of 2.76% as of Jul. 22, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Orexo AB and its competitors.
Is Orexo AB's Institutional Ownership too high?
Orexo AB's current Institutional Ownership is 2.76%. Overall, Orexo AB has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Orexo AB's Institutional Ownership compare to ZTS and UTHR?
Orexo AB's Institutional Ownership of 2.76% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Orexo AB and its competitors. Orexo AB's current Institutional Ownership is 2.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orexo AB stock overvalued right now?
Orexo AB (CHIX:ORXS) has a current Institutional Ownership of 2.76%. The stock's GF Value™ is kr7.46, compared to a current price of kr30.95 — trading 314.9% above its estimated fair value. The current Institutional Ownership is 2.76%. Orexo AB's overall GF Score™ is 41/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Orexo AB (CHIX:ORXS), the current Institutional Ownership is 2.76% as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orexo AB (CHIX:ORXS) Overvalued in 2026?

Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued. The current stock price of kr30.95 is trading 314.9% above its estimated GF Value™ of kr7.46.

Key valuation signals for CHIX:ORXS:

  • Institutional Ownership: 2.76%
  • GF Value™: kr7.46 vs. price of kr30.95 (314.9% above fair value)
  • GF Score™: 41/100 with 7 warning signs

No single metric tells the full story. See the CHIX:ORXS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Orexo AB Business Description

Address Virdings alle 22, Uppsala, SWE, 75105
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
41GF Score

Get the complete analysis for CHIX:ORXS

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr30.95
Price
kr7.46
GF Value